Finerenone for Patients With Primary Aldosteronism (FAIRY)
Status:
RECRUITING
Trial end date:
2026-06-01
Target enrollment:
Participant gender:
Summary
Using spironolactone as the control, to assess the efficacy and safety of finerenone in patients with primary aldosteronism(PA).
Phase:
PHASE4
Details
Lead Sponsor:
Qifu Li
Collaborators:
Changzhi Medical College Second Affiliated Hospital, School of Medicine, Zhejiang University The Affiliated Hospital Of Southwest Medical University The First Affiliated Hospital of Zhengzhou University